Theravance study results confirm in vitro potency of VIBATIV Theravance announced new data from multiple studies of VIBATIV. These study results, which offer new insight into the product's in vitro potency, efficacy and safety, will be the focus of multiple presentations over the next several days at the 24th European Congress of Clinical Microbiology and Infectious Diseases in Barcelona, Spain. Combined, the data presentations confirm the in vitro potency of VIBATIV and its efficacy in patients with complicated skin and skin structure infections including methicillin-resistant Staphylococcus aureus.
Credit Suisse to hold a conference Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 13 at 11 am; not all company presentations may be webcasted. Webcast Link